ABSTRACT Background: Rheumatoid arthritis (RA)
INTRODUCTION heumatoid arthritis (RA)
is an inflammatory autoimmune disease characterized by joint swelling, inflammation, progressive erosions and articular cartilage destruction leading to structural damage and permanent disability [1] . Cytokines play an important role in the processes that cause inflammation, articular destruction and extra-articular manifestations [2] . IL-23 is mainly secreted by activated macrophages and dendritic cells [3] . IL-23 is a proinflammatory cytokine responsible for maintaining balance between regulatory and effectors T-cell response, and it is an important factor for development of T-cell dependent inflammatory response. IL-23 has a key role in chronic inflammation, which is a common characteristic of several autoimmune diseases through, two independent pathways. The first pathway is by the activation of Th17 cells and the second by the induction of the secretion of IL-17 by non-T cells [4] . IL-23 promotes Th17 cells producing IL-6, IL-17, IL-22, Tumour necrosis factor-α (TNF-α), and granulocyte-monocyte colony-stimulating factor (GM-CSF) [2] . IL-23 has an essential role in other chronic autoimmune diseases as inflammatory bowel disease (IBD) [5] and psoriasis [6] and Behҁet's disease [7] . In this study, we aimed to evaluate IL-23 level in the sera of RA patients in comparison to the healthy controls and to determine its relation with disease activity.
Subjects and Methods
This study was carried out in Rheumatology and Rehabilitation and Clinical Pathology Departments, Faculty of Medicine, Zagazig University Hospitals. Two groups were included in the study: group I included Forty patients (37 females and 3 males) with RA diagnosed according to 2010 American college of Rheumatology / European League Against Rheumatism (ACR/EULAR) classification criteria for RA [8] , group II included 40 healthy subjects (32 females and 8 males) taken as control matched for age and sex with the patients. Written consent was signed by the RA patients and healthy controls.
This study was approved by the institutional review board (IRB) of the faculty. Patients with other inflammatory autoimmune diseases, including systemic lupus erythromatosis (SLE), scleroderma, ankylosing spondylitis, psoriasis, Behcets disease and inflammatory bowel diseases were excluded from the study. Rheumatoid arthritis disease activity was evaluated by DAS-28 [9] . All patients were subjected to full history taking, thorough clinical examination, radiological and laboratory investigations including complete blood count, erythrocyte sedimentation rate (ESR) [10] , CRP was detected by immunohistochemistry, rheumatoid factor (RF) by nephelometry method, using automated analyzer and anticyclic citrullinated peptide ( anti-CCP) antibodies [11] . Measurement of serum interleukin-23 level was performed by a commercial enzyme-linked immune sorbent assay (ELISA) kit for RA patients and controls. According to the instruction of the manufacturer by Sun Red international trade company, Shanghai, China. Serum samples were collected from patients on the same day of examination.
STATISTICAL ANALYSIS The collected data were computerized and statistically analyzed using SPSS program (Statistical Package for Social Science) version 18.0. RESULTS Demographic data of RA patients and healthy controls included in the study: RA patient's ages ranged between 23-62 years with a mean of 43.25 ± 10.44, while the control subjects ages ranged between18 -65 years with a mean of 39.5 ± 12.65. There was no statistically significant difference between the two groups as regards age, sex distribution or number of smokers (table1). The mean value of IL-23 serum level showed a highly statistically significant difference between RA patients and controls. It was 67.55 ± 39.21 pg/ml in RA patients and 37.72± 15.64 pg/ml in the healthy controls (P <0.001) ( Table 2) . There was a statistically significant difference in IL-23 level between RA patients with different grades of DAS28. The highest level was detected in patients with high disease activity (Table 3) . (Table 5) . IL-23 at a cut off value of 45 (pg/ml), had a sensitivity of 77.8% and a specificity of 75% for detection of moderate and high disease activity. . 
DISCUSSION
This study was conducted to determine the role of IL-23 in RA as a marker of disease activity in RA patients. Our study showed that the level of IL -23 in RA patients was significantly elevated in comparison to healthy controls. This significant elevation in IL-23 level in RA patients was reported by previous studies [12, 13, 14] . In our study, there was non-significant correlation between each of the age, sex, number of swollen or tender joints and disease duration with IL-23 level. These results were matched with those of Zaky and El-Nahrery [13] , who did not find correlations between IL-23 and clinical data of patients as duration of the disease and the number of affected joints. In contrast to our results, Fadda et al. [12] , found significant correlation between serum IL-23 levels and swollen and tender joints, but not with disease duration in RA patients.
One of the main findings of our study is the significant correlation between serum IL-23 levels and different grades of DAS-28. Thus, higher serum IL-23 levels indicate higher disease activity in patients with RA. Our results are in agreement with other studies [12, 14, 16] . In contrast with our results, a study by Zaky and El-Nahrery [13] .revealed no significant correlation between IL-23 and disease activity measured by DAS-28. However, these contradictory results may be related to differences among the RA patients as regards to medications administered. About the drug treatment, all patients were receiving disease modifying anti-rheumatic drugs (DMARDs). None of them was receiving biologics. IL-23 level was significantly decreased in RA patients, in parallel with the clinical remission in responders after anti-TNF-α therapy [15] [16] [17] .
In this study, serum levels of IL-23 were significantly correlated with ESR, CRP, RF and anti-CCP antibodies. In agreement with our results, Fadda et al. [12] mentioned that there were significant correlations between IL-23 and ESR, CRP and RF titer. Our results revealed no significant association between physical damage (radiographic joint damage) and IL-23 levels. This finding indicates that serum IL-23 levels correlate with disease activity but not with joint damage. CONCLUSION IL-23 levels were significantly increased in patients with RA compared with healthy controls. Its significant correlation with DAS-28 suggested that serum IL-23 level could be a useful marker of disease activity in RA. Direct IL-23 blockade may be an important key in controlling RA disease activity.
